Further analysis showed that the K2 residue of HMGN2 was deacetylated in primary breast tumors but highly acetylated in normal human breast tissue, implying that targeting HMGN2 deacetylation may be a viable treatment for this type of breast cancer [55]. Here, HMGN2 is linked to breast neoplasm.